Navigation Links
Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
Date:3/26/2008

Conference Call to be Held on Thursday, March 27, 2008

(7:00 p.m. Singapore Time and 7:00 a.m. Eastern Time)

SINGAPORE and MOUNTAIN VIEW, Calif., March 26 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Bio*One Capital Pte. Ltd., one of the largest dedicated biomedical investment management companies in Asia, has committed to purchase $10 million of common stock in Alexza. The investment by Bio*One is being made in conjunction with Alexza's formation of Alexza Singapore Pte. Ltd., a wholly owned subsidiary. Alexza intends to initiate manufacturing operations for key components of Alexza's single-dose Staccato(R) device in Singapore. Alexza's single-dose Staccato devices are used in a majority of its current product candidates, including its lead program, AZ-004 (Staccato loxapine), which is in Phase 3 clinical testing for the treatment of acute agitation in schizophrenic or bipolar disorder patients.

"A key element of Alexza's commercial manufacturing strategy is the development of production for the Staccato device-related plastic and electronics components of our commercial product single-dose device," said Thomas B. King, President and CEO of Alexza. "Singapore provides an excellent location and environment for us to establish this important aspect of our commercial manufacturing plan. I believe the rich talent pool and in-depth expertise available in Singapore will be a key element for successful manufacturing operations."

"Alexza's technology and Staccato device offer patients a new paradigm to rapid systemic drug delivery through deep lung inhalation. We believe that combining Alexza's unique technology and Singapore's strengths in medical technology will f
'/>"/>

SOURCE Alexza Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
9. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
10. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
11. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 2015 , ... Ralco is honored to announce that it is the primary ... held August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where ... impacts their daily lives. This unique exhibit also features a birthing center for fair ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... appointed Francois Vieillard as Sales & Marketing Director. , With more than ... will be responsible for reinforcing Tronics’ business development activities worldwide. He brings to ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... completion of a field clinical study of its canine osteoarthritis stem cell product, ... Aratana Therapeutics (Kansas City, KS) and will be marketed in the US by ...
(Date:7/30/2015)... across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s ... reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in Calgary ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today announced ... its partner and licensee for perifosine in the North ... Food and Drug Administration (FDA) regarding a Special Protocol ...
... - OncoGenex Pharmaceuticals (NASDAQ: OGXI ) announced today ... Thursday, August 6, 2009. OncoGenex will host a conference call ... discuss quarterly results. , The webcast can be accessed on ... www.oncogenex.com . Alternatively, you may access the live conference ...
... The years of ... big breakthrough in the search for a viable alternative feedstock for biodiesel in combination with ... happy to announce the much awaited commercial release of Couple oil crop cultivation (COC) technology. ... (PRWEB) August 3, 2009 ...
Cached Biology Technology:AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 4Jatropha Couple Oil Crop Cultivation Technology Commercially Released 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 3
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Scientists have discovered that autoimmunity can be triggered in the ... cells fail to recognize just one of the body's thousands ... view that autoimmunity can start in this cradle of the ... diseases emerge, such as the pancreas in the case of ...
... rising over the last two decades, and new research from ... increase is driven largely by the detection of small, presumably ... been paralleled by greater use of surgery for kidney cancer, ... "With increased early detection and treatment of small tumors, we ...
... without predators - at least this was the case up ... with cats and dogs on some islands of the Archipelago. ... in order to discover if such generally tame animals are ... novel predation threats. Scientists from the Max Planck Institute for ...
Cached Biology News:Autoimmune disease triggered if T cells miss a single protein early on 2Autoimmune disease triggered if T cells miss a single protein early on 3More kidney cancer is detected and treated early, yet death rate rises 2More kidney cancer is detected and treated early, yet death rate rises 3Too mellow for our predatory world 2Too mellow for our predatory world 3Too mellow for our predatory world 4
Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Profilin-1/2 (FL-140)...
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
Biology Products: